A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

NCT00001271 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

B Cell Lymphoma

Interventions

DRUG: IgG-RFB4-SMPT-dgA

Sponsor

National Cancer Institute (NCI)